14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VTYX vs AMLX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Amylyx Pharmaceuticals, Inc. (AMLX) on higher Unified Composite conviction (50.4/100 HOLD vs. 59.8/100 HOLD) after splitting the core matrix 2–6 (led by Growth & Scale, Options & Positioning), while AMLX wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus AMLX at $28.08 (2.8x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AMLX currently prints a higher short-term Unified Composite Score (59.8/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -99.6% YoY).
Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile AMLX is in a Breakdown options structure phase (RSI 46.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs AMLX. Trailing 12-month operating profitability (VTYX 0.0% vs AMLX 0.0%) and valuation multiples (VTYX N/M vs AMLX 2.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.8B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VTYX vs AMLX Key Questions & Quantitative Answers
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Amylyx Pharmaceuticals, Inc. (AMLX) on higher Unified Composite conviction (50.4/100 HOLD vs. 59.8/100 HOLD) after splitting the core matrix 2–6 (led by Growth & Scale, Options & Positioning), while AMLX wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus AMLX at $28.08 (2.8x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AMLX currently prints a higher short-term Unified Composite Score (59.8/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -99.6% YoY). Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile AMLX is in a Breakdown options structure phase (RSI 46.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VTYX leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AMLX at -99.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus N/A for AMLX. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AMLX.
AMLX screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AMLX trades at 2.8x Forward P/E, 2.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus AMLX (-30.1% ROE) capital efficiency.
In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, AMLX carries 61.4% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.17β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.